Chetan S. Karyekar

The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers

Gary H. Kamimori, Chetan S. Karyekar, Ronald Otterstetter et al. · International Journal of Pharmaceutics · 2002 · 376 citations

Physiology, Oral Hygiene, Relative Bioavailability +2

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Paul Emery, Gerd R Burmester, Vivian P. Bykerk et al. · Annals of the Rheumatic Diseases · 2014 · 232 citations · Full text

Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease

Thomas C. Dowling, Andrew Briglia, Jeffrey C. Fink et al. · Clinical Pharmacology & Therapeutics · 2003 · 119 citations · Full text

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Philip J. Mease, Philip Helliwell, Dafna D. Gladman et al. · The Lancet Rheumatology · 2021 · 94 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Laura C. Coates, Laure Gossec, Elke Theander et al. · Annals of the Rheumatic Diseases · 2021 · 92 citations · Full text